



October 31, 2014

Akebia to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participate in two upcoming investor conferences:

- Presentation at the Nomura Biotechnology Conference on Thursday, November 6, at 11:00 a.m. Eastern Time
- Presentation at the 2014 Credit Suisse Healthcare Conference on Wednesday, November 12, at 1:30 p.m. Mountain Time

A live audio webcast of the presentations will be available on the company's website at <http://ir.akebia.com/events.cfm>. An archived presentation will be available for 90 days.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. Akebia's lead product candidate, AKB-6548, is a once-daily, oral therapy, which has completed a Phase 2b study for the treatment of anemia related to CKD in non-dialysis patients and is in a Phase 2 study for the treatment of anemia in patients undergoing dialysis. For more information on Akebia, please visit www.akebia.com.

Investors:

Akebia Therapeutics, Inc.
Nicole P. Jones, +1-617-871-1210
Senior Director, Investor Relations and Corporate Communications
njones@akebia.com

or

Media:

Feinstein Kean Healthcare
Liz Falcone, +1-617-761-6727
liz.falcone@fkhealth.com

Source: Akebia Therapeutics, Inc.

News Provided by Acquire Media